Dr. Jennifer M. Specht
Claim this profileSeattle Cancer Care Alliance / University of Washington
Studies Breast Cancer
Studies Breast cancer
10 reported clinical trials
18 drugs studied
Area of expertise
1Breast Cancer
Stage IV
HER2 positive
Stage III
2Breast Cancer
HER2 positive
HER2 negative
ER positive
Affiliated Hospitals
Clinical Trials Jennifer M. Specht is currently running
Niraparib + Dostarlimab
for Breast Cancer
This research study involves pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA and PALB2 mutations. The names of the study drugs involved in this study are: * Niraparib (Zejula) * Dostarlimab
Recruiting1 award Phase 211 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
More about Jennifer M. Specht
Clinical Trial Related3 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Jennifer M. Specht has experience with
- Fludeoxyglucose F-18
- Pembrolizumab
- Ladiratuzumab Vedotin
- Trastuzumab
- Niraparib
- Computed Tomography
Breakdown of trials Jennifer M. Specht has run
Breast Cancer
Breast cancer
Skin Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jennifer M. Specht specialize in?
Jennifer M. Specht focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are HER2 positive.
Is Jennifer M. Specht currently recruiting for clinical trials?
Yes, Jennifer M. Specht is currently recruiting for 4 clinical trials in Seattle Washington. If you're interested in participating, you should apply.
Are there any treatments that Jennifer M. Specht has studied deeply?
Yes, Jennifer M. Specht has studied treatments such as Fludeoxyglucose F-18, Pembrolizumab, ladiratuzumab vedotin.
What is the best way to schedule an appointment with Jennifer M. Specht?
Apply for one of the trials that Jennifer M. Specht is conducting.
What is the office address of Jennifer M. Specht?
The office of Jennifer M. Specht is located at: Seattle Cancer Care Alliance / University of Washington, Seattle, Washington 98109 United States. This is the address for their practice at the Seattle Cancer Care Alliance / University of Washington.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.